Esperion Therapeutics Inc. (NASDAQ:ESPR) currently has a daily average trading volume of 6.85M but it saw 8782902 shares traded in last market. With a market cap of 393.67M USD, the company’s current market price of $2.31 came falling about -8.33 while comparing to the previous closing price of $2.52. In past 52 weeks, the stock remained buoying in the range of price level as high as $3.40 and as low as $0.70.
Taking a look at 20-day trading activity of Esperion Therapeutics Inc. (ESPR) gives us an average price of $2.56, while its current price level is -32.06% below from 52-week high level whereas it is 230.00% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $2.51 while that of 200 days or SMA-200 reads an average of $1.76. A closer look into the stock’s movement over the week reveals that its volatility is standing at 13.93% during that period while stretching the period over a month that decreases to 12.19%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 41.92 which implies that the stock is in neutral territory.
Over the week, ESPR’s stock price is moving -25.72% down while it is 12.68% when we observe its performance for the past one month. Year-to-date it is -22.74% down and over the past year, the stock is showing an upside performance of 86.29%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of -$0.5 beaten by the consensus estimate of -$0.48 for the same. For ESPR, analysts are forecasting an EPS-growth rate of 80.30% for current year and estimate for EPS growth in next year is 112.50%. In next quarter, company is expected to be making quarterly sales of $42.53 million as analysts are expecting the sales for current fiscal year at $265.13 million and seeing the company making $391.03 million in sales next year. Moreover, analysts are in estimates of $84.51 million for current-quarter revenue.
Currently, Esperion Therapeutics Inc.’s total number of outstanding shares is 170.42M with 0.80% of that held by the insiders while 41.69% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -422.11%. It has a 43.90 of forward P/E ratio. Stock’s beta reads 0.83. Stock has a price to sale or P/S ratio amounts to 3.38. Its return on asset (ROA) is -92.23% on average.
